Strides Arcolab specialties unit Agila has received US FDA approval for clindamycin injection, USP, an antibiotic used to treat bacterial infections. This product is manufactured under the Strides – Sagent joint venture. clindamycin is the twelfth product approved under the Sagent - Strides partnership and the latter is developing- supplying more than 25 injectable products for the USA market which will be marketed by Sagent.
Clindamycin features the Prevent IV Measures packaging and labelling designed to aid in the reduction of medication errors. The Injection will be available in three single-dose vial sizes and in pharmacy bulk packaging. The product is expected to be launched in early 2012.
According to IMS, the 2011 US market for Injectable Clindamycin approximates to US$ 65 million.
Agila is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company’s restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 8 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.
Strides Arcolab is a global pharmaceutical company that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.
The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.